TY - JOUR T1 - Activity and phenotypes of angiotensin-converting enzyme (ACE) in sarcoidosis with various organ involvement JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2020.1087 VL - 56 IS - suppl 64 SP - 1087 AU - Laine Francuzevica AU - Alexander Bobkov AU - Larisa Akulkina AU - Michael Brovko AU - Victoria Sholomova AU - Denis Konovalov AU - Alisa Yanakaewa AU - Larisa Samokhodskaya AU - Tatyana Krasnova Y1 - 2020/09/07 UR - http://erj.ersjournals.com/content/56/suppl_64/1087.abstract N2 - Background: There is a lack of special serologic markers associated with the distinct organ involvement in sarcoidosis. Although total angiotensin-converting enzyme (ACE) activity is nonspecific, different ACE phenotypes may serve as more selective sarcoidosis markers.Methods: Authors observed 89 patients with sarcoidosis in 2019-2020. ACE activity in plasma (compared with normal plasma) has been measured to distinguish the ACE phenotypes. Two substrates - HHL (hippuryl-L-histidyl-L-leucine) and ZPHL (carbobenzoxy-L-phenylalaninyl-L-histidyl-L-leucine), and ACE binding with specific autoantibodies – 9B9, 1G12 - have been compared in patients with different organ involvement. Quantitative parameters are expressed as median [25 percentile; 75 percentile].Results: ACE activity and binding with specific autoantibodies were comparable in patients with isolated pulmonary sarcoidosis and systemic extrapulmonary involvement.In patients with liver involvement (n=19), ACE activity with 1G12, Z/H and 1G12/9В9 was significantly higher than in patients without it (154[104;290]% vs 92[70;122]%, р=0,047; 140[97;164]% vs 96[90;103]%, р=0,02 and 134[81;231]% vs 81[73;99]%, р=0,044, respectively).In patients with central nervous system involvement (n=14), ACE activity with 1G12/9В9 (109,5[79,5;192,8]% vs 80,5[73%;94,8], р=0,05) was higher than in patients without it.Conclusion: In patients with sarcoidosis different ACE phenotypes are associated with liver and central nervous system involvement and should be measured to evaluate the risk of extrapulmonary lesions.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 1087.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -